Remus Pharmaceuticals Reports Strong Financial Performance for FY26, Declares Dividend

Remus Pharmaceuticals Reports Strong Financial Performance for FY26, Declares Dividend​

Remus Pharmaceuticals Limited announced its financial results for the half year and the full financial year ended March 31, 2026. The company reported significant growth in revenue, citing the strong performance of its B2C entity, Relius, as a major driver of its success.

The Board of Directors convened its meeting on May 20, 2026, and approved a final dividend of Rs. 0.50 per Equity Share for the Financial Year 2025-26, which is subject to approval by the shareholders at the ensuing Annual General Meeting.

Financial Highlights (FY26 vs FY25)​

Remus Pharmaceuticals reported robust financial metrics across the full year, indicating substantial growth year-over-year (YoY).

In the consolidated results, Total Income saw a significant increase, achieving ₹ 860.33 Crore in FY26, up from ₹ 625.34 Crore in FY25, marking a 37.60% YoY growth in Revenue from Operations. The consolidated EBITDA for FY26 was ₹ 56.69 Crore, showing a 24.08% growth compared to ₹ 45.69 Crore in FY25. Net Profit After Tax (PAT) also grew to ₹ 46.17 Crore in FY26, up from ₹ 38.42 Crore in FY25, reflecting a 20.18% YoY increase.

The company’s half-year (H2) consolidated performance for FY26 was ₹ 453.43 Crore in Revenue from Operations, a 30.39% jump from the ₹ 347.75 Crore reported in H2 FY25.

Standalone and Consolidated Financial Data (₹ in Crore)​

The comprehensive audited results provide a detailed overview of the financial performance:


The consolidated results show Total Income of ₹ 457.20 Crore for the half year ended March 31, 2026, compared to ₹ 350.38 Crore for the same period in 2025.

Operational and Strategic Milestones​

On the operational front, Remus Pharmaceuticals highlighted several achievements aimed at expanding its global footprint and product portfolio:

• Portfolio Strengthening: The company in-licensed Rifaximin (200 mg & 550 mg) and Fexofenadine 180 mg for key markets including Mexico, Chile, Vietnam, and Peru, enhancing its anti-infective and anti-allergy segment.
• Tender Successes: Remus secured a direct government tender in Nicaragua for Ceftazidime + Avibactam 2.5 g Injection and was awarded the NUPCO tender for Topiramate capsules in Saudi Arabia.
• Emerging Markets Focus: Filing initiatives were initiated for Semaglutide tablets and injections across non-patented emerging markets through both B2B and B2C channels, signaling a push into the GLP-1 and anti-obesity segment.
• Geographic Expansion: The company expanded its commercial presence into four new markets: Myanmar, Nicaragua, North Macedonia, and Madagascar.
• Regulatory Clearance: The company successfully cleared the Peru DIGEMID audit in February 2026, further bolstering its regulatory credibility across Latin American markets.

Governance and Auditing Updates​

The Board Meeting also addressed corporate governance through the appointment of external auditors.

• Secretarial Audit: Mr. Tapan Shah, Practicing Company Secretary, was appointed as the Secretarial Auditor for the Financial Year 2026-27.
• Internal Audit: Sharp & Tannan Associates, Chartered Accountants, was appointed as the Internal Auditor for the Financial Year 2026-27.

The financial results for the period ended March 31, 2026, were audited by Pankaj R. Shah & Associates, Chartered Accountants, and were issued with an unmodified opinion.

In the consolidated audit, the financial results include the audit of multiple subsidiaries, including Relius Pharma SRL, Espee Global Holdings LLC, Relius Pharmaceuticals Limitada, and Espee Global Clinical Trial Services Pvt. Ltd., alongside a step down subsidiary, Espee Biopharma & Fine Chem LLC.

REMUS Stock Price Movement​

Remus Pharmaceuticals Limited shares today slipped by 4.26% to settle at ₹866.35 in post-market action. The stock completed trading with a reported volume of 36,300 shares.